期刊
PHARMACOGENOMICS
卷 18, 期 5, 页码 445-458出版社
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2016-0204
关键词
aminoacylase 3; atenolol; bisoprolol; genome-wide; hypertension; losartan; nephrin; pharmacogenomics
资金
- Sigrid Juselius Foundation
- Finnish Foundation for Cardiovascular Research
- Blueprint Genetics, Inc.
- Metabolon, Inc.
Aim To replicate the genome-wide associations of the antihypertensive effects of bisoprolol and losartan in GENRES, using the Finnish patients of LIFE study. Patients & methods: We analyzed association of four SNPs with atenolol and three SNPs with losartan response in 927 Finnish LIFE patients (467 for atenolol and 460 for losartan). Results: rs2514036, a variation at a transcription start site of ACY3, was associated with blood pressure response to atenolol in men in LIFE. Response to bisoprolol was correlated to baseline plasma levels of N-acetylphenylalanine and phenylalanine (ACY3 substrate and end product, respectively) in GENRES study. NPHS1 variation rs3814995 was associated with losartan effect in LIFE. Conclusion: We provide support for two pharmacogenomic markers for beta-blockers and angiotensin receptor antagonists.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据